[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA27451A1 - Derives de thiazole pour le traitement de troubles neurodegeneratifs - Google Patents

Derives de thiazole pour le traitement de troubles neurodegeneratifs

Info

Publication number
MA27451A1
MA27451A1 MA28206A MA28206A MA27451A1 MA 27451 A1 MA27451 A1 MA 27451A1 MA 28206 A MA28206 A MA 28206A MA 28206 A MA28206 A MA 28206A MA 27451 A1 MA27451 A1 MA 27451A1
Authority
MA
Morocco
Prior art keywords
treatment
neurodegenerative disorders
formula
thiazole derivatives
compounds
Prior art date
Application number
MA28206A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Michael Leon Corman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27451A1 publication Critical patent/MA27451A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 9 Octobre 2002 60/417,400 US 17 Juin 2003 10/463,209 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de thiazole pour le traitement de troubles Neurodégénératifs La présente invention propose des composés de formule (I) : dans laquelle R1, R2, R3, R4, R6, R7 et A sont tels que définis. Les composés de formule (I) ont une activité inhibitrice de production du peptide A(bêta). La présente invention propose également des compositions pharmaceutiques et méthodes pour le traitement de maladies, par exemple de la maladie d'Alzeihmer, chez des mammifères, comprenant des composés de formule (I).
MA28206A 2002-10-09 2005-04-08 Derives de thiazole pour le traitement de troubles neurodegeneratifs MA27451A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
US46320903A 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
MA27451A1 true MA27451A1 (fr) 2005-07-01

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28206A MA27451A1 (fr) 2002-10-09 2005-04-08 Derives de thiazole pour le traitement de troubles neurodegeneratifs

Country Status (28)

Country Link
US (1) US20040152747A1 (fr)
EP (1) EP1551815A1 (fr)
JP (1) JP2006504796A (fr)
KR (1) KR20050070046A (fr)
CN (1) CN1688557A (fr)
AP (1) AP2005003274A0 (fr)
AR (1) AR043051A1 (fr)
AU (1) AU2003265068A1 (fr)
BR (1) BR0314611A (fr)
CA (1) CA2501803A1 (fr)
CO (1) CO5550435A2 (fr)
CR (1) CR7785A (fr)
EC (1) ECSP055719A (fr)
GT (1) GT200300219A (fr)
IS (1) IS7738A (fr)
MA (1) MA27451A1 (fr)
MX (1) MXPA05002420A (fr)
NL (1) NL1024499C2 (fr)
NO (1) NO20052223L (fr)
OA (1) OA12937A (fr)
PA (1) PA8585001A1 (fr)
PE (1) PE20040640A1 (fr)
PL (1) PL376171A1 (fr)
TN (1) TNSN05104A1 (fr)
TW (1) TW200420550A (fr)
UY (1) UY28011A1 (fr)
WO (1) WO2004033439A1 (fr)
ZA (1) ZA200502841B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2006525990A (ja) * 2003-05-12 2006-11-16 ファイザー・プロダクツ・インク 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
MXPA06001480A (es) * 2003-08-06 2006-05-15 Pfizer Prod Inc Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2005073226A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole, leur preparation et leur application en therapeutique
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
DK1709018T3 (da) * 2004-01-16 2011-11-14 Sanofi Sa Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
DE602005007717D1 (de) * 2004-03-23 2008-08-07 Pfizer Prod Inc Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
US7384968B2 (en) * 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
MX2007001727A (es) 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
US7888379B2 (en) * 2005-05-24 2011-02-15 Merck Serono Sa Thiazole derivatives and use thereof
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
WO2007034326A2 (fr) * 2005-09-22 2007-03-29 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques
US8105581B2 (en) 2005-12-01 2012-01-31 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation
EP1981884B1 (fr) * 2006-01-18 2012-06-13 Amgen, Inc Composés thiazoliques comme inhibiteurs de protéine kinase b
ATE538108T1 (de) * 2006-11-05 2012-01-15 Max Planck Gesellschaft Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
CA2731097A1 (fr) * 2008-07-15 2010-01-21 Novartis Ag Composes organiques
US8889670B2 (en) 2009-02-18 2014-11-18 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the CB2 receptor
WO2010126002A1 (fr) * 2009-04-28 2010-11-04 塩野義製薬株式会社 Produit pharmaceutique contenant un composé sulfonamide hétérocyclique
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2595959B1 (fr) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Composés sulfonylés qui modulent le récepteur cb2
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
CA2899088C (fr) * 2013-03-14 2022-12-20 Merck Patent Gmbh Composes de thiazole et d'oxazole en tant qu'inhibiteurs de glycosidase
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508135A (ja) * 1991-05-28 1994-09-14 メルク　エンド　カンパニー　インコーポレーテッド 抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
SK16282000A3 (sk) * 1998-05-01 2001-05-10 Abbott Laboratories Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
GT200300219A (es) 2004-05-18
UY28011A1 (es) 2004-04-30
ZA200502841B (en) 2006-03-29
CA2501803A1 (fr) 2004-04-22
US20040152747A1 (en) 2004-08-05
JP2006504796A (ja) 2006-02-09
MXPA05002420A (es) 2005-10-05
IS7738A (is) 2005-03-10
PA8585001A1 (es) 2004-12-16
CR7785A (es) 2005-07-08
PE20040640A1 (es) 2004-09-15
NL1024499C2 (nl) 2004-10-13
AU2003265068A1 (en) 2004-05-04
PL376171A1 (en) 2005-12-27
BR0314611A (pt) 2005-07-26
TW200420550A (en) 2004-10-16
OA12937A (en) 2006-10-13
NL1024499A1 (nl) 2004-04-13
ECSP055719A (es) 2005-07-06
EP1551815A1 (fr) 2005-07-13
CO5550435A2 (es) 2005-08-31
AR043051A1 (es) 2005-07-13
AP2005003274A0 (en) 2005-06-30
NO20052223L (no) 2005-07-04
NO20052223D0 (no) 2005-05-06
WO2004033439A1 (fr) 2004-04-22
CN1688557A (zh) 2005-10-26
KR20050070046A (ko) 2005-07-05
TNSN05104A1 (fr) 2007-05-14

Similar Documents

Publication Publication Date Title
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA27132A1 (fr) Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
MA27444A1 (fr) Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27452A1 (fr) Derives d'indole servant d'agonistes beta-2
MA27442A1 (fr) Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
CA2501799A1 (fr) Composes pyrazole pour le traitement de maladies neurodegeneratives
MA27079A1 (fr) Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes
TNSN06200A1 (fr) Derives de quinoleine nouveaux
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
MA27440A1 (fr) Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1